R&D In The IRA Era: Takeda Opts Not To Develop Zasocitinib For Lupus

The TYK2 inhibitor is in Phase III development for plaque psoriasis and psoriatic arthritis but the company said it will not pursue late-stage studies in lupus, partly due to the Inflation Reduction Act.